Clarke Low

Thanks @NarjustFlorezMD and @Florez_Lab for the beautiful pin to raise awareness of lung cancer, especially in women. #hearher #LCSM

@PEHP2 please send DM so we can discuss a patient with Stage IV NSCLC needing to start chemoIO. PA submitted 1/6, being told no guarantee by 1/19. This is delaying care to patient's detriment. FDA-approved, NCCN-recommended treatment. 😠#FixPriorAuth #ASCOAdvocacy #LCSM

CNS-only progression for patient on 1L entrectenib for ROS1 disease. Likely too many for gamma knife. What would you do? #LCSM

@Dr_RShatsky Becky—I once had a 24 hour period where 4 of my patients died. It was sooo hard. I don’t think training prepares us for the loss that we all carry. I find comfort in my hope and belief that after this life I will see my patients again and give them a giant hug.

Losing patients seems to happen in waves in oncology. The grief can sometimes be overwhelming. I miss my patients who I have lost every day. I think back on each one’s case thinking is there anything else I could have done? #onctwitter #bcsm

Presentations by medical students/residents/fellows are the best. So exciting to have young colleagues share their perspective and enthusiasm. #ASCO2022

@CharuAggarwalMD @ASCO @DrRiyazShah @DrJNaidoo @christine_lovly @LealTiciana @HwakeleeMD @LeciaSequist @JackWestMD @DrSteveMartin @ADesaiMD @esinghimd Unfortunate trial was terminated early as the difference was not statistically significant. Also, Squam having higher MPR was not seen in CM816. Question of just not enough patients or difference in biology with different populations?

For early stage, resectable NSCLC - How many cycles of neo-adjuvant chemo-immunotherapy do we need? NeoSCORE Trial looked at MPR as primary endpoint, with carbo-nab pac, or pem + sintilimab ✴️MPR: 3 cyc slightly better than 2 ✴️ Sq higher MPR #LCSM #ASCO22 @ASCO

Tempting to say receipt of adjuvant chemo for early stage NSCLC is a med onc quality metric, however, we must acknowledge some of this is not necessarily modifiable. A lot of patients aren't enthused by 5% OS benefit, for PD-L1 neg, EGFR neg pt's. #LCSM

Congrats on great talk by @BrendanHeiden on developing operative quality score on early stage, N0, NSCLC. Might be most important talk I've heard so far, truly a #cancergroundshot #ASCO22 #LCSM. What would med onc and rad onc quality parameters look like...

Good panel on treatment sequencing for NSCLC. First time I have ever heard treatment deescalation for lung cancer. I know we have had some progress, but deescalation seems a bit premature, no? #ASCO22 #LCSM

@marklewismd @Shemari_12 Amen. I learn so much from my patients. And my colleagues cc: @marklewismd

@Shemari_12 They’re incredible. I learn from them constantly. Cc: @ClarkeLow

Was sitting with a patient at their deathbed and saying how sorry I was that I couldn't sustain them further when they quoted Ecclesiastes to me: "To every thing there is a season: a time to be born, and a time to die.” Once again, I'm not always sure who is comforting whom here.

@ALKLungCancer Looking for a clinical trial for pt who progressed on alectinib, then lorlatinib. Lives in Western US. Any recommendations? #LCSM

So proud to work with @MVanMeterMD at @intermtncancer Great summary at @SUMOncology #ASCO21 update meeting on lingering questions from OlympiA trial.

Still waiting for @marklewismd to pull a Dwight Schrute at @SUMOncology

“With virtual meetings we don’t return to the office because we never left the office.” @marklewismd speaks truth at a fantastic in-person meeting in Salt Lake by @SUMOncology. Great to be in-person.

Grateful to be back at an in-person meeting and learning at the feet of my mentor ⁦@WAkerleyMD⁩ from ⁦@huntsmancancer⁩. Great update of progress in lung Ca. Thanks ⁦@SUMOncology⁩ for hosting this great event. #LCSM

I miss in-person meeting, but I really like the question format with voting and moderators to select the questions. Far superior to random questions at the microphone. Please @ASCO find a way to keep this. #ASCO21

@dean_fennell Congratulations on great presentation. Love changing "best supportive care" to "active symptom control" and including on both arms. #LCSM #ASCO21

I don't tweet often, but I want to highlight practice changing stuff. Presser on IMpower010 (adj atezo, St II-IIIA NSCLC post chemo) is potentially that. HR 0.66 for recurrence/death in PD-L1 expressing NSCLC. Can't wait to see more data. Congrats @HwakeleeMD. #LCSM #ASCO21

15min phone call w/ PBM for prior auth for selpercatinib that was denied. Questions are confusing to me, let alone my staff. Seems like they are designed to lead to denial. Love getting questions from "peer" who cannot pronounce hypocalcemia or hypomagnesemia. Sigh. #MedTwitter

Really,really great @NEJM commentary: bit.ly/3anZpU1. What can I always offer my patients: "giving someone the space to be known". Simple, but profound. Thx @LisaRosenbaum17 for your beautiful writing.